​

Aardvark Therapeutics (AARD) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

AARD Stock Forecast

Aardvark Therapeutics (AARD) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $24.00, with a high of $24.00 and a low of $24.00. This represents a 143.16% increase from the last price of $9.87.

AARD Stock Rating

Aardvark Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

AARD Price Target Upside V Benchmarks

TypeNameUpside
StockAardvark Therapeutics143.16%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$24.00$26.50
Last Closing Price$9.87$9.87$9.87
Upside/Downside-143.16%168.49%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 2534---7
Oct, 2534---7
Sep, 2532---5
Aug, 2532---5
Jul, 2532---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 29, 2025Stifel Nicolaus$24.00$13.2381.41%143.16%
Mar 10, 2025Morgan Stanley$29.00$9.98190.58%193.82%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 10, 2025Morgan StanleyOverweightinitialise

Financial Forecast

EPS Forecast

Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported------
Avg Forecast$-2.86$-2.63$-2.57$-2.92$-1.89$-0.79
High Forecast$-2.86$-1.62$-2.50$-2.92$-1.89$-0.79
Low Forecast$-2.86$-3.68$-2.70$-2.92$-1.89$-0.79
Surprise %------

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported------
Avg Forecast--$750.00K$20.09M$116.36M$241.16M
High Forecast--$750.00K$20.09M$116.36M$241.16M
Low Forecast--$750.00K$20.09M$116.36M$241.16M
Surprise %------

Net Income Forecast

$-50M $-42M $-34M $-26M $-18M $-10M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-20.59M-----
Avg Forecast$-36.86M$-33.97M$-33.55M$-37.70M$-24.33M$-10.13M
High Forecast$-36.86M$-20.97M$-32.24M$-37.70M$-24.33M$-10.13M
Low Forecast$-36.86M$-47.54M$-34.85M$-37.70M$-24.33M$-10.13M
Surprise %-44.14%-----

AARD Forecast FAQ

Is Aardvark Therapeutics stock a buy?

Aardvark Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Aardvark Therapeutics is a favorable investment for most analysts.

What is Aardvark Therapeutics's price target?

Aardvark Therapeutics's price target, set by 4 Wall Street analysts, averages $24 over the next 12 months. The price target range spans from $24 at the low end to $24 at the high end, suggesting a potential 143.16% change from the previous closing price of $9.87.

How does Aardvark Therapeutics stock forecast compare to its benchmarks?

Aardvark Therapeutics's stock forecast shows a 143.16% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Aardvark Therapeutics over the past three months?

  • November 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 60.00% Strong Buy, 40.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Aardvark Therapeutics’s EPS forecast?

Aardvark Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.63, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $-2.57 in 2026, $-2.92 in 2027, $-1.89 in 2028, and $-0.79 in 2029.

What is Aardvark Therapeutics’s revenue forecast?

Aardvark Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $750K, followed by $20.09M for 2027, $116.36M for 2028, and $241.16M for 2029.

What is Aardvark Therapeutics’s net income forecast?

Aardvark Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-33.971M, representing an 65.00% increase from the reported $-20.588M in 2024. Projections indicate $-33.547M in 2026, $-37.695M in 2027, $-24.334M in 2028, and $-10.134M in 2029.